- Home
- LIXT vs ALLR Comparison
LIXT vs ALLR Comparison
Compare LIXT & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- ALLR
- Stock Information
- Founded
- LIXT 2005
- ALLR 2004
- Country
- LIXT United States
- ALLR United States
- Employees
- LIXT N/A
- ALLR N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- LIXT Health Care
- ALLR Health Care
- Exchange
- LIXT Nasdaq
- ALLR Nasdaq
- Market Cap
- LIXT 4.1M
- ALLR 4.0M
- IPO Year
- LIXT N/A
- ALLR N/A
- Fundamental
- Price
- LIXT $1.17
- ALLR $0.87
- Analyst Decision
- LIXT
- ALLR
- Analyst Count
- LIXT 0
- ALLR 0
- Target Price
- LIXT N/A
- ALLR N/A
- AVG Volume (30 Days)
- LIXT 17.8K
- ALLR 660.5K
- Earning Date
- LIXT 05-12-2025
- ALLR 05-09-2025
- Dividend Yield
- LIXT N/A
- ALLR N/A
- EPS Growth
- LIXT N/A
- ALLR N/A
- EPS
- LIXT N/A
- ALLR N/A
- Revenue
- LIXT N/A
- ALLR N/A
- Revenue This Year
- LIXT N/A
- ALLR N/A
- Revenue Next Year
- LIXT N/A
- ALLR N/A
- P/E Ratio
- LIXT N/A
- ALLR N/A
- Revenue Growth
- LIXT N/A
- ALLR N/A
- 52 Week Low
- LIXT $1.02
- ALLR $0.61
- 52 Week High
- LIXT $3.50
- ALLR $20.44
- Technical
- Relative Strength Index (RSI)
- LIXT 41.14
- ALLR 36.97
- Support Level
- LIXT $1.28
- ALLR $1.02
- Resistance Level
- LIXT $1.41
- ALLR $1.06
- Average True Range (ATR)
- LIXT 0.12
- ALLR 0.08
- MACD
- LIXT -0.01
- ALLR -0.03
- Stochastic Oscillator
- LIXT 3.23
- ALLR 12.56
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.